The nonprofit, The Endometriosis Collective, has included Schumer and Monroe in the feature-length documentary “End of the ...
More biopharma layoffs are hitting New Jersey, this time from Merck & Co.in the latest phase of headcount reductions ...
After submitting its timed-release version of a decades-old ADHD drug to the FDA nearly a year ago, Kansas City's Cingulate ...
As governments and health authorities rush to meet the moment of a worsening Ebola outbreak in central Africa, Merck & Co. is considering dusting off its antiviral molnupiravir, which saw use as a ...
Amid shifts in attitudes around family planning and contraception—and as the advent of telehealth outfits like Hims & Hers and Ro defines a new era of consumer-driven healthcare—the lack of a ...
A phase 3 study of Gilead’s Livdelzi has met its primary endpoint, showing the drug's ability to normalize a key marker of disease progression for those with the rare liver disorder primary biliary ...
Eisai has partnered with CaringKind to expand its nutrition support initiative to cover Alzheimer's disease and related dementias (ADRDs). The Japanese drugmaker created its “Magnolia Meals at Home” ...
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | ...
ViiV Healthcare is teaming up with TV personality, HIV and LGBTQ advocate Michelle Visage to help broaden awareness about new ...
AstraZeneca is polishing the case for its Imfinzi (durvalumab) and Imjudo (tremelimumab) combo in liver cancer with a new ...
Combination strategies are rapidly redefining treatment for HER2-positive solid tumors. | HER2 combination strategies are ...
Merck & Co.’s extensive clinical development scheme for its TROP2 antibody-drug conjugate (ADC) sac-TMT already ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results